WallStSmart

Moolec Science SA Ordinary Shares (MLEC)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moolec Science SA Ordinary Shares generates 956% more annual revenue ($7.83M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. MLEC earns a higher WallStSmart Score of 44/100 (D).

MLEC

Hold

44

out of 100

Grade: D

Growth: 6.3Profit: 3.0Value: 5.0Quality: 3.0
Piotroski: 4/9Altman Z: -1.80

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MLEC1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
948.0%10/10

Revenue surging 948.0% year-over-year

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

MLEC4 concerns · Avg: 3.5/10
Price/BookValuation
11.6x4/10

Trading at 11.6x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.27M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MLEC

The strongest argument for MLEC centers on Revenue Growth. Revenue growth of 948.0% demonstrates continued momentum.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : MLEC

The primary concerns for MLEC are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 7.21 is elevated, increasing financial risk.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

MLEC profiles as a hypergrowth stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

MLEC is growing revenue faster at 948.0% — sustainability is the question.

MLEC generates stronger free cash flow (-30M), providing more financial flexibility.

Bottom Line

MLEC scores higher overall (44/100 vs 24/100) and 948.0% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Moolec Science SA Ordinary Shares

HEALTHCARE · BIOTECHNOLOGY · USA

Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company is headquartered in Luxembourg.

Visit Website →

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?